What do systematic reviews say?

Dopamine agonist vs placebo or no intervention

Dopamine agonist probably leads to lower incidence of moderate or severe OHSS compared with placebo/no intervention (moderate certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.32 [0.23, 0.44]
  10 studies · 1202 participants
  Moderate

Dopamine agonist vs other active intervention

It is very uncertain whether dopamine agonist changes incidence of moderate or severe OHSS compared with other active intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.21 [0.12, 0.38]
  3 studies · 296 participants
  Very low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in live birth rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.08 [0.73, 1.59]
  2 studies · 430 participants
  Low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with other active intervention (moderate certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 1.04 [0.81, 1.33]
  7 studies · 1060 participants
  Moderate

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in multiple pregnancy rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.87 [0.47, 1.59]
  3 studies · 400 participants
  Low

Dopamine agonist vs other active intervention

Dopamine agonist showed no clear difference in miscarriage rate compared with other active intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.66 [0.35, 1.25]
  4 studies · 630 participants
  Low

Dopamine agonist vs other active intervention

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 170 participants
  GRADE not reported

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in live birth rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.96 [0.6, 1.55]
  3 studies · 362 participants
  Low

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in clinical pregnancy rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.92 [0.63, 1.37]
  5 studies · 530 participants
  Low

Dopamine agonist vs placebo or no intervention

It is very uncertain whether dopamine agonist changes multiple pregnancy rate compared with placebo/no intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.32 [0.01, 8.26]
  1 study · 40 participants
  Very low

Dopamine agonist vs placebo or no intervention

Dopamine agonist showed no clear difference in miscarriage rate compared with placebo/no intervention (low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 0.66 [0.19, 2.28]
  2 studies · 168 participants
  Low

Dopamine agonist vs placebo or no intervention

It is very uncertain whether dopamine agonist changes any other adverse events compared with placebo/no intervention (very low certainty).

• Dopamine agonists for preventing ovarian hyperstimulation syndrome 2021 · Cochrane Headline outcomes only
  OR 4.54 [1.49, 13.84]
  2 studies · 264 participants
  Very low

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in dropouts compared with placebo (moderate certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.94, 1.14]
  20 studies · 1656 participants
  Moderate

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in adverse events as N of participants with at least one adverse event compared with placebo (moderate certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.27 [0.66, 2.44]
  7 studies · 252 participants
  Moderate

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in abstinence (objective) Participants abstinent at the end of… compared with placebo (low certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.12 [0.85, 1.47]
  11 studies · 731 participants
  Low

Dopamine agonist vs placebo

Any dopamine agonist showed no clear difference in abstinence at compared with placebo (low certainty).

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  RR 1.1 [0.61, 1.98]
  4 studies · 136 participants
  Low

Dopamine agonist vs placebo

• Dopamine agonists for the treatment of cocaine dependence 2015 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 202 participants
  Low

Dopamine antagonists vs placebo

It is very uncertain whether dopamine antagonists changes nausea ‐ intraoperative compared with placebo (very low certainty).

• Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
  RR 0.38 [0.27, 0.52]
  15 studies · 1180 participants
  Very low
• Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
  RR 0.61 [0.48, 0.79]
  7 studies · 601 participants
  Low

Dopamine antagonists vs placebo

Dopamine antagonists may leads to lower vomiting ‐ intraoperative compared with placebo (low certainty).

• Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
  RR 0.41 [0.28, 0.6]
  12 studies · 942 participants
  Low

Dopamine antagonists vs placebo

It is very uncertain whether dopamine antagonists changes vomiting ‐ postoperative compared with placebo (very low certainty).

• Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section 2021 · Cochrane Headline outcomes only
  RR 0.63 [0.44, 0.92]
  9 studies · 860 participants
  Very low